Lewington V J
Nuclear Medicine, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.
Endocr Relat Cancer. 2003 Dec;10(4):497-501. doi: 10.1677/erc.0.0100497.
Evidence supporting the potential contribution of targeted radiotherapy to the management of neuroendocrine tumours is now strong. Acting systemically, this is an effective option for patients with inoperable or multi-site disease. Toxicity is generally low, being limited to reversible myelosuppression and theoretical nephrotoxicity. Prerequisites for treatment success include demonstration of high tumour uptake relative to non-target tissues on quantitative diagnostic radionuclide imaging and stable haematological and biochemical function. In addition to (131)I metaiodobenzylguanidine therapy, which is now well established, there is growing interest in radiolabelled peptide therapy using a range of somatostatin receptor analogues such as (90)Y DOTATOC and (90)Y lanreotide. The results of clinical experience are summarised and the direction for future research is discussed.
目前，支持靶向放疗对神经内分泌肿瘤治疗具有潜在作用的证据十分充分。作为一种全身治疗手段，对于无法手术或多部位病变的患者而言，这是一种有效的选择。其毒性通常较低，仅限于可逆性骨髓抑制和理论上的肾毒性。治疗成功的前提条件包括在定量诊断性放射性核素成像中显示肿瘤相对于非靶组织有高摄取，以及血液学和生化功能稳定。除了现已成熟的（131）I间碘苄胍治疗外，人们对使用一系列生长抑素受体类似物如（90）Y DOTATOC和（90）Y兰瑞肽进行放射性标记肽治疗的兴趣也在不断增加。本文总结了临床经验结果并讨论了未来的研究方向。
